Free Trial
NASDAQ:CMPX

Compass Therapeutics (CMPX) Stock Price, News & Analysis

$1.47
-0.03 (-1.67%)
(As of 05/24/2024 08:49 PM ET)
Today's Range
$1.46
$1.52
50-Day Range
$1.44
$2.25
52-Week Range
$1.15
$3.45
Volume
108,500 shs
Average Volume
423,927 shs
Market Capitalization
$202.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Compass Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
512.2% Upside
$9.00 Price Target
Short Interest
Bearish
1.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of Compass Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.41) to ($0.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.37 out of 5 stars

Medical Sector

556th out of 922 stocks

Biological Products, Except Diagnostic Industry

85th out of 153 stocks

CMPX stock logo

About Compass Therapeutics Stock (NASDAQ:CMPX)

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

CMPX Stock Price History

CMPX Stock News Headlines

Compass Therapeutics Inc Ordinary Shares
See More Headlines
Receive CMPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
5/26/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CMPX
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$10.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+512.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-42,490,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.14 per share

Miscellaneous

Free Float
96,312,000
Market Cap
$202.26 million
Optionable
Not Optionable
Beta
0.92
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Vered Bisker-Leib M.D. (Age 53)
    MBA, Ph.D., CEO & Director
    Comp: $719k
  • Dr. Thomas J. Schuetz M.D. (Age 63)
    Ph.D., Co-Founder, President of Research & Development and Vice Chairman of the Board
    Comp: $835.88k
  • Mr. Neil L. Lerner CPA (Age 57)
    Vice President of Finance
  • Mr. Jonathan Anderman J.D.
    VP, Head of Legal & Corporate Secretary
  • Anna Gifford
    Communications Manager
  • Dr. Minori Rosales M.D. (Age 61)
    Ph.D., Senior VP & Head of Clinical Development
  • Ms. Karin Herrera B.A.
    VP & Head of Clinical Operations
  • Dr. James Kranz Ph.D.
    VP and Head of Chemistry Manufacturing & Controls

CMPX Stock Analysis - Frequently Asked Questions

Should I buy or sell Compass Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMPX shares.
View CMPX analyst ratings
or view top-rated stocks.

What is Compass Therapeutics' stock price target for 2024?

2 brokerages have issued 12 month price objectives for Compass Therapeutics' shares. Their CMPX share price targets range from $8.00 to $10.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 512.2% from the stock's current price.
View analysts price targets for CMPX
or view top-rated stocks among Wall Street analysts.

How have CMPX shares performed in 2024?

Compass Therapeutics' stock was trading at $1.56 at the start of the year. Since then, CMPX stock has decreased by 5.8% and is now trading at $1.47.
View the best growth stocks for 2024 here
.

When is Compass Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our CMPX earnings forecast
.

How were Compass Therapeutics' earnings last quarter?

Compass Therapeutics, Inc. (NASDAQ:CMPX) announced its earnings results on Thursday, March, 21st. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02.

When did Compass Therapeutics IPO?

Compass Therapeutics (CMPX) raised $50 million in an initial public offering (IPO) on the week of November 16th 2020. The company issued 9,000,000 shares at $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel served as the underwriters for the IPO and Raymond James was co-manager.

Who are Compass Therapeutics' major shareholders?

Compass Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (4.72%), Vanguard Group Inc. (3.02%), CM Management LLC (0.23%), Simplicity Wealth LLC (0.03%), Bleakley Financial Group LLC (0.03%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Carl L Gordon, Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib.
View institutional ownership trends
.

How do I buy shares of Compass Therapeutics?

Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMPX) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners